Navigation Links
Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
Date:7/30/2008

Company's Fourth FDA 510(k) Clearance Since December 2007

WAYNE, Pa., July 30 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced that the United States Food and Drug Administration ("FDA") has cleared the 510(k) submission for the LIASYS(TM) bench top clinical chemistry and immunoturbidimetric analyzer. The Company's recently acquired JAS Diagnostic ("JAS") unit is the distributor for the LIASYS analyzer in the United States and supplier of the associated chemistry reagents. JAS prepared and submitted the 501(k) application on behalf of the manufacturer, Analyzer Medical System, headquartered in Rome, Italy. The analyzer is being introduced at the 2008 Annual Meeting for the American Association for Clinical Chemistry ("AACC") currently being held in Washington D.C.

LIASYS is a fully automatic random access, continuous loading, easy access bench top clinical chemistry and immunoturbidimetric analyzer. The instrument features primary tubes sampling, capacitive liquid level sensing, positive identification of the samples, and module for ion selective electrode ("ISE"). It is suitable to perform the daily routine of low/medium-sized laboratories in an entirely safe and reliable way, providing flexible and cost effective solutions. The LIASYS multitasking and user-friendly software enhances the system's potential and performance.

"We believe this is an attractive chemistry analyzer that offers an excellent combination of sampling speed, precision, reliability, and ease of use," commented David Johnston, President of JAS Diagnostics. "We have optimized and validated a broad range of dedicated reagents for LIASYS and anticipate benefiting directly from an ongoing chemistry reagent revenue st
'/>"/>

SOURCE Escalon Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
2. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
3. Escalon(R) Announces Executive Promotions
4. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
5. Escalon(R) Reports First Quarter Fiscal 2008 Results
6. Escalon(R) Reports Financial Results for 2007 Fiscal Year
7. French Agency Receives 10 Million Dollar Grant From the Bill & Melinda Gates Foundation to Support the Establishment of National Vaccine Advisory Committees in Africa and Asia
8. Pandemic research receives $1.6M funding boost
9. Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi
10. Greater Medical Center Group Receives Major Funding From MELCO Investments
11. NJHA Receives Planning Grant from RWJF for Regional Market Quality Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... roles two proteins, thrombospondin-1 and prosaposin, play in ... identified a five-amino acid fragment of prosaposin that ... prostate, breast and lung cancer. The findings suggest ... in a variety of cancers. , The ... Boston Children,s Hospital, Vivek Mittal, PhD, at Weill ...
(Date:5/21/2013)... the removal of the adenoids and tonsils, is performed ... as a treatment for children with obstructive sleep apnea. ... attention and executive functioning, behavior, sleep apnea symptoms, and ... now. A study led by Susan Redline, MD, ... Cardiovascular Medicine and Associate Clinic Director of the Division ...
(Date:5/21/2013)... Harbor, Florida (PRWEB) May 21, 2013 ... agency, announced today that they have redesigned their website ... a nude beach, pool, hot tubs, bars and dining. ... this nudist resort including sales and guest reviews, will ... island of Jamaica itself, including pages on culinary local ...
(Date:5/21/2013)... The American Diabetes Association ( http://goo.gl/YRSF1 ... United States of America are affected with peripheral neuropathy. ... risk of developing peripheral neuropathy which unfortunately makes it ... further goes on saying that the disease usually affects ... million new cases are diagnosed every year in the ...
(Date:5/21/2013)... Aggressive treatment for prostate cancer may not be ... conditions, a new study finds. Treatments for ... seed implants, can cause serious side effects, such ... explained researchers from the University of California, Los ... patients with slower growing forms of prostate cancer ...
Breaking Medicine News(10 mins):Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2
... Two Chinese soybean lines that grow without the primary ... have been isolated by scientists//. ,The two lines ... given away to breeders seeking to produce new varieties ... scientists at the University of Illinois at Urbana-Champaign and ...
... into action by mutations of the virus into a human flu ... what plan of action can we rely on to control the ... countries are teaming up next month to roll out a mock ... a pandemic. ,Australia and Singapore will be co-coordinating the ...
... of the out of hours health care system in England as ... ,The public accounts committee claimed that the new health care ... many key targets. ,In 2004 most GPs had opted ... PCTs took over in 90% of cases. ,The NAO ...
... plans for slow suffocation of millions of poultry, in ... ,According to Compassion in World Farming (CIWF) ... have been amended under emergency procedures whereby the Secretary ... a method of culling poultry in the event of ...
... a type 1 diabetic has been reported missing in West ... of medication// leaving her gravely ill, police have appealed for ... home in Uphall, at 2 pm on Monday. Stephanie went ... in Livingston. She is white, 5 ft 2in, of stocky ...
... University in Scotland found that women with high levels ... following in vitro fertilization. They found that the supplement ... after fertility treatment. ,However, the researchers said ... birth defects such as spina bifida, does not affect ...
Cached Medicine News:Health News:Promise for Soya Allergy Sufferers 2Health News:High Levels Of Folic Acid May Increase The Chances Of Twins After IVF 2
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... -- U.S. spending on specialty prescription drugs — those ... multiple sclerosis and rheumatoid arthritis — is projected to ... to a forecast released today by Express Scripts (NASDAQ: ... "As we see what,s on the horizon, ... so they can continue to offer an affordable pharmacy ...
(Date:5/21/2013)... , May 21, 2013  AcelRx Pharmaceuticals, ... specialty pharmaceutical company focused on the development ... treatment of acute and breakthrough pain, today ... placebo-controlled Phase 3 study of its investigational ... (NanoTab System), the primary efficacy endpoint was ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... REDWOOD CITY, Calif., May 6, 2011 AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today announced that Richard King, President and Chief Executive ... Research Conference at the San Francisco Ritz Carlton. The ...
... MIAMI, May 6, 2011 SaveRxCanada.com the premier Canadian pharmacy ... still purchase Canada drugs from a Canada pharmacy ... Canada drugs can be 85% less than the U.S. ... clientele since 2002. 2. Convenience – Many patients are ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference 2Canadian Pharmacy Intermediary's Top Reasons U.S. Customers Choose Canada Online Pharmacies Revealed by SaveRxCanada.com 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: